<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The French-American-British (FAB) classification assigns patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> to the category of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) if they have a medullary blast count of 5-20%, and/or a peripheral blast count of 2-5% </plain></SENT>
<SENT sid="1" pm="."><plain>The new World Health Organization (WHO) classification subdivides <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> into <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> with a medullary blast count &lt; or =10% and a peripheral blast count &lt; or =5% and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> with &gt;10% medullary and/or &gt;5% peripheral blasts </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> is also diagnosed if Auer rods are present </plain></SENT>
<SENT sid="3" pm="."><plain>In 558 patients, we analysed these subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in terms of haematological characteristics, karyotype anomalies and prognosis </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> was diagnosed in 256 and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> in 302 patients </plain></SENT>
<SENT sid="5" pm="."><plain>In the <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> group, 22% of patients had &gt;5% peripheral blasts or the presence of Auer rods </plain></SENT>
<SENT sid="6" pm="."><plain>The median survival was 16 months for <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> as compared with 9 months for <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB II</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with Auer rods, regardless of their medullary and peripheral blast count, had no worse prognosis </plain></SENT>
<SENT sid="8" pm="."><plain>No significant differences were identified between the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> subtypes with respect to clinical, morphological, haematological and cytogenetic parameters </plain></SENT>
<SENT sid="9" pm="."><plain>The survival data support the WHO reclassification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> based on peripheral and medullary blast counts and Auer rods </plain></SENT>
<SENT sid="10" pm="."><plain>The WHO classification is useful for diagnosis and provides risk stratification, supported by cytogenetic data for clinical decision making, identifying those <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients with an unfavourable prognosis who should be offered chemotherapy or stem cell transplantation </plain></SENT>
</text></document>